Rosuvastatin efficacy
Pro Research Analysisby 
Searched over 200M research papers for "rosuvastatin efficacy"
Rosuvastatin Efficacy in Lowering LDL Cholesterol and Improving Lipid Profiles
Multiple studies consistently show that rosuvastatin is highly effective at lowering low-density lipoprotein cholesterol (LDL-C) and improving overall lipid profiles in patients with hypercholesterolemia and dyslipidemia. In direct comparisons, rosuvastatin at both 5 mg and 10 mg doses produced greater reductions in LDL-C (39.1% and 47.4%, respectively) than equivalent doses of pravastatin and simvastatin, with more patients reaching their LDL-C goals after 52 weeks of treatment . Systematic reviews confirm that rosuvastatin at 10–40 mg/day can decrease LDL-C by 46% to 55%, and it is about three times more potent than atorvastatin for LDL-C reduction . These findings are supported by additional research showing that rosuvastatin at daily doses of 5–40 mg achieves mean LDL-C reductions of 45–63%, outperforming atorvastatin, simvastatin, and pravastatin at equivalent doses .
Dose-Response Relationship and Potency Compared to Other Statins
The cholesterol-lowering effect of rosuvastatin is linearly dependent on dose, with higher doses leading to greater reductions in total cholesterol, LDL-C, and non-HDL cholesterol . Increasing the dose from 10 mg to 20 mg can result in an additional LDL-C reduction of approximately 40% . This strong dose-response relationship makes rosuvastatin a flexible option for achieving lipid targets in a wide range of patients Adams2017Mckenney2005Sirenko2020.
Efficacy in Special Populations and Combination Therapies
Rosuvastatin has demonstrated efficacy in various patient groups, including those with metabolic syndrome and moderate to severe metabolic associated fatty liver disease (MAFLD). In a 52-week study, rosuvastatin 10 mg/day significantly reduced liver fat content and improved lipid parameters without compromising safety . In children with homozygous familial hypercholesterolemia (HoFH), rosuvastatin 20 mg led to a mean LDL-C reduction of 22.3%, with efficacy observed regardless of age or concurrent treatments such as ezetimibe or apheresis . Additionally, a fixed-dose combination of rosuvastatin and valsartan was effective in patients with both hypertension and hyperlipidemia, with 75.9% achieving LDL-C targets after 12 weeks .
Additional Benefits and Non-Lipid Effects
Beyond cholesterol lowering, rosuvastatin has shown beneficial effects in other areas. It can reduce triglycerides and increase HDL cholesterol by about 7%, contributing to a more favorable lipid profile Adams2017Mckenney2005Sirenko2020. Rosuvastatin also exhibits anti-inflammatory, antioxidant, and antithrombotic properties, which may provide added cardiovascular protection . In patients with chronic periodontitis, locally delivered rosuvastatin gel improved periodontal health and bone regeneration compared to placebo . Furthermore, rosuvastatin has been shown to enhance the therapeutic efficacy of stem cell therapy for myocardial infarction by improving cell survival and heart function .
Safety Profile
Across studies, rosuvastatin has demonstrated a safety profile similar to other statins, with no significant increase in adverse events compared to placebo in short-term trials Brown2002Adams2017Mckenney2005+4 MORE. It is generally well tolerated, and most patients can remain on their starting dose without the need for frequent adjustments .
Conclusion
Rosuvastatin is a highly effective statin for lowering LDL cholesterol and improving lipid profiles, with greater potency than many other statins. Its efficacy is consistent across diverse patient populations and clinical scenarios, and it is generally well tolerated. Rosuvastatin’s additional benefits, such as improvements in triglycerides, HDL cholesterol, and non-lipid effects, further support its role as a valuable option in the management of dyslipidemia and cardiovascular risk.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
Rosuvastatin effectively lowers LDL cholesterol and non-HDL-cholesterol levels, enabling more patients to reach their LDL cholesterol goals with an acceptable safety profile compared to other statins.
DOI